Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

George Miltiades Eliopoulos, M.D.

TitleProfessor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
Dept. of Medicine
One Deaconess Rd
Boston MA 02215
Phone617/632-7434
Fax617/632-7439

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC, Eliopoulos GM, Peleg AY. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis. 2012 Jun; 205(11):1677-87.
    View in: PubMed
  2. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Eliopoulos GM. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One. 2012; 7(1):e28316.
    View in: PubMed
  3. Joukhadar C, Pillai S, Wennersten C, Moellering RC, Eliopoulos GM. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother. 2010 Feb; 54(2):773-7.
    View in: PubMed
  4. Galloway-Peña JR, Nallapareddy SR, Arias CA, Eliopoulos GM, Murray BE. Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States. J Infect Dis. 2009 Nov 15; 200(10):1566-73.
    View in: PubMed
  5. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis. 2009 Oct 15; 49(8):1169-74.
    View in: PubMed
  6. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect. 2009 Sep; 59 Suppl 1:S17-24.
    View in: PubMed
  7. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother. 2009 Jun; 53(6):2605-9.
    View in: PubMed
  8. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis. 2009 Feb 15; 199(4):532-6.
    View in: PubMed
  9. Peleg AY, Tilahun Y, Fiandaca MJ, D'Agata EM, Venkataraman L, Moellering RC, Eliopoulos GM. Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa. J Clin Microbiol. 2009 Mar; 47(3):830-2.
    View in: PubMed
  10. Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC, Mylonakis E. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14585-90.
    View in: PubMed
  11. Gqada Z, Marais B, Wasserman E, Bamford C, Orth H, Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC, Eliopoulos GM. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008 Jul; 46(7):2471; author reply 2471-2.
    View in: PubMed
  12. Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC, Eliopoulos GM. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008 Jan; 46(1):220-4.
    View in: PubMed
  13. Tsakris A, Pillai SK, Gold HS, Thauvin-Eliopoulos C, Venkataraman L, Wennersten C, Moellering RC, Eliopoulos GM. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus. J Antimicrob Chemother. 2007 Sep; 60(3):649-51.
    View in: PubMed
  14. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother. 2007 Jun; 51(6):2223-5.
    View in: PubMed
  15. Sung H, Shin HB, Kim MN, Lee K, Kim EC, Song W, Jeong SH, Lee WG, Park YJ, Eliopoulos GM. Vancomycin-tolerant Streptococcus pneumoniae in Korea. J Clin Microbiol. 2006 Oct; 44(10):3524-8.
    View in: PubMed
  16. Eliopoulos GM. Enterococci: on the back burner but still simmering. Curr Infect Dis Rep. 2006 Sep; 8(5):333-6.
    View in: PubMed
  17. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006 Apr; 50(4):1581-5.
    View in: PubMed
  18. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006 Apr; 57(4):699-704.
    View in: PubMed
  19. Sakoulas G, Moellering RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis. 2006 Jan 1; 42 Suppl 1:S40-50.
    View in: PubMed
  20. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis. 2005 Dec; 24(12):826-31.
    View in: PubMed
  21. Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC. In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria. Antimicrob Agents Chemother. 2005 Jul; 49(7):3034-9.
    View in: PubMed
  22. Sakoulas G, Eliopoulos GM, Fowler VG, Moellering RC, Novick RP, Lucindo N, Yeaman MR, Bayer AS. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother. 2005 Jul; 49(7):2687-92.
    View in: PubMed
  23. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother. 2005 Mar; 55 Suppl 2:ii5-13.
    View in: PubMed
  24. Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC, Jenkins SG. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother. 2004 Oct; 54(4):818-20.
    View in: PubMed
  25. Fowler VG, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis. 2004 Sep 15; 190(6):1140-9.
    View in: PubMed
  26. Pillai SK, Sakoulas G, Eliopoulos GM, Moellering RC, Murray BE, Inouye RT. Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis. J Infect Dis. 2004 Sep 1; 190(5):967-70.
    View in: PubMed
  27. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC, Gold HS. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004 Jul 15; 190(2):311-7.
    View in: PubMed
  28. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004 Jun; 42(6):2398-402.
    View in: PubMed
  29. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004 Jun 15; 38(12):1700-5.
    View in: PubMed
  30. Eliopoulos GM. Quinolone resistance mechanisms in pneumococci. Clin Infect Dis. 2004 May 15; 38 Suppl 4:S350-6.
    View in: PubMed
  31. Eliopoulos GM. Current and new antimicrobial agents. Am Heart J. 2004 Apr; 147(4):587-92.
    View in: PubMed
  32. Person RE, Li FQ, Duan Z, Benson KF, Wechsler J, Papadaki HA, Eliopoulos G, Kaufman C, Bertolone SJ, Nakamoto B, Papayannopoulou T, Grimes HL, Horwitz M. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet. 2003 Jul; 34(3):308-12.
    View in: PubMed
  33. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1714-8.
    View in: PubMed
  34. Sakoulas G, Gold HS, Venkataraman L, Moellering RC, Ferraro MJ, Eliopoulos GM. Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility. J Antimicrob Chemother. 2003 Apr; 51(4):1039-41.
    View in: PubMed
  35. Sakoulas G, Eliopoulos GM, Moellering RC, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis. 2003 Mar 15; 187(6):929-38.
    View in: PubMed
  36. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003 Feb 15; 36(4):473-81.
    View in: PubMed
  37. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC, Ferraro MJ, Gold HS. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis. 2002 Dec 1; 186(11):1603-7.
    View in: PubMed
  38. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28; 162(19):2223-8.
    View in: PubMed
  39. Eliopoulos GM, Wennersten CB, Moellering RC. In vitro activity of the new oxazolidinone AZD2563 against Enterococci. Antimicrob Agents Chemother. 2002 Oct; 46(10):3273-5.
    View in: PubMed
  40. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis. 2002 Aug; 8(8):802-7.
    View in: PubMed
  41. Pillai SK, Sakoulas G, Gold HS, Wennersten C, Eliopoulos GM, Moellering RC, Inouye RT. Prevalence of the fsr locus in Enterococcus faecalis infections. J Clin Microbiol. 2002 Jul; 40(7):2651-2.
    View in: PubMed
  42. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, Novick RP, Gold HS. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002 May; 46(5):1492-502.
    View in: PubMed
  43. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002 May; 46(5):1319-24.
    View in: PubMed
  44. Baden LR, Critchley IA, Sahm DF, So W, Gedde M, Porter S, Moellering RC, Eliopoulos G. Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. J Clin Microbiol. 2002 Apr; 40(4):1160-3.
    View in: PubMed
  45. Baden LR, Horowitz G, Jacoby H, Eliopoulos GM. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA. 2001 Dec 26; 286(24):3115-9.
    View in: PubMed
  46. Sakoulas G, Gold HS, Venkataraman L, DeGirolami PC, Eliopoulos GM, Qian Q. Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol. 2001 Nov; 39(11):3946-51.
    View in: PubMed
  47. Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, Moellering RC, Eliopoulos GM. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis. 2001 Nov 15; 33(10):1654-60.
    View in: PubMed
  48. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001 Sep; 45(9):2628-30.
    View in: PubMed
  49. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001 Jul 21; 358(9277):207-8.
    View in: PubMed
  50. Torres Viera C, Tsiodras S, Gold HS, Coakley EP, Wennersten C, Eliopoulos GM, Moellering RC, Inouye RT. Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. Antimicrob Agents Chemother. 2001 Mar; 45(3):973-5.
    View in: PubMed
  51. Boucher HW, Thauvin-Eliopoulos C, Loebenberg D, Eliopoulos GM. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis. Antimicrob Agents Chemother. 2001 Jan; 45(1):208-11.
    View in: PubMed
  52. Carmeli Y, Castro J, Eliopoulos GM, Samore MH. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Antimicrob Agents Chemother. 2001 Jan; 45(1):275-9.
    View in: PubMed
  53. Batts DH, Lavin BS, Eliopoulos GM. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report. Curr Clin Top Infect Dis. 2001; 21:227-51.
    View in: PubMed
  54. Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC, Quinn JP, Hindler J, Medeiros AA, Bush K. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother. 2000 Nov; 44(11):3035-9.
    View in: PubMed
  55. Tsiodras S, Gold HS, Coakley EP, Wennersten C, Moellering RC, Eliopoulos GM. Diversity of domain V of 23S rRNA gene sequence in different Enterococcus species. J Clin Microbiol. 2000 Nov; 38(11):3991-3.
    View in: PubMed
  56. Souli M, Thauvin-Eliopoulos C, Eliopoulos GM. In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis. Antimicrob Agents Chemother. 2000 Oct; 44(10):2733-9.
    View in: PubMed
  57. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother. 2000 Aug; 44(8):2225-9.
    View in: PubMed
  58. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, Sofia RD, Eliopoulos GM. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 2000 Jun; 44(6):1720-4.
    View in: PubMed
  59. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis. 2000; 32(6):651-6.
    View in: PubMed
  60. Schülin T, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1999 Dec; 43(12):2873-6.
    View in: PubMed
  61. Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C, Venkataraman L, Samore MH, Tenover FC, Eliopoulos GM, Moellering RC, Gold HS. A cluster of VanD vancomycin-resistant Enterococcus faecium: molecular characterization and clinical epidemiology. J Infect Dis. 1999 Oct; 180(4):1177-85.
    View in: PubMed
  62. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999 Jun; 43(6):1379-82.
    View in: PubMed
  63. D'Agata EM, Venkataraman L, DeGirolami P, Burke P, Eliopoulos GM, Karchmer AW, Samore MH. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med. 1999 Jun; 27(6):1090-5.
    View in: PubMed
  64. Eliopoulos GM. Activity of newer fluoroquinolones in vitro against gram-positive bacteria. Drugs. 1999; 58 Suppl 2:23-8.
    View in: PubMed
  65. Schülin T, Wennersten CB, Moellering RC, Eliopoulos GM. In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. J Antimicrob Chemother. 1998 Sep; 42(3):297-301.
    View in: PubMed
  66. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother. 1998 Jun; 42(6):1520-3.
    View in: PubMed
  67. Eliopoulos GM, Wennersten CB, Gold HS, Schülin T, Souli M, Farris MG, Cerwinka S, Nadler HL, Dowzicky M, Talbot GH, Moellering RC. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother. 1998 May; 42(5):1088-92.
    View in: PubMed
  68. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents. 1998 Apr; 10(1):23-30.
    View in: PubMed
  69. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC, Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1997 Dec; 41(12):2749-53.
    View in: PubMed
  70. Eliopoulos GM. Vancomycin-resistant enterococci. Mechanism and clinical relevance. Infect Dis Clin North Am. 1997 Dec; 11(4):851-65.
    View in: PubMed
  71. Eliopoulos GM, Wennersten CB. In vitro activity of trimethoprim alone compared with trimethoprim-sulfamethoxazole and other antimicrobials against bacterial species associated with upper respiratory tract infections. Diagn Microbiol Infect Dis. 1997 Sep; 29(1):33-8.
    View in: PubMed
  72. Schülin T, Wennersten CB, Moellering RC, Eliopoulos GM. In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother. 1997 May; 41(5):1196-202.
    View in: PubMed
  73. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1997 May; 41(5):1053-7.
    View in: PubMed
  74. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 1996 Jul; 40(7):1745-7.
    View in: PubMed
  75. Eliopoulos GM, Wennersten CB, Moellering RC. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis. 1996 May; 25(1):35-41.
    View in: PubMed
  76. Eliopoulos GM. Antibiotic resistance in Enterococcus species: an update. Curr Clin Top Infect Dis. 1996; 16:21-51.
    View in: PubMed
  77. Cercenado E, Unal S, Eliopoulos CT, Rubin LG, Isenberg HD, Moellering RC, Eliopoulos GM. Characterization of vancomycin resistance in Enterococcus durans. J Antimicrob Chemother. 1995 Nov; 36(5):821-5.
    View in: PubMed
  78. Eliopoulos GM, Wennersten CB, Cole G, Moellering RC. In vitro activity of WY-49605, a penem antimicrobial. Int J Antimicrob Agents. 1995 Jul; 5(4):251-7.
    View in: PubMed
  79. Malanoski G, Collins L, Eliopoulos CT, Moellering RC, Eliopoulos GM. Comparative in vitro activities of L-695,256, a novel carbapenem, against gram-positive bacteria. Antimicrob Agents Chemother. 1995 Apr; 39(4):990-5.
    View in: PubMed
  80. Eliopoulos GM, Wennersten CB, Cole G, Chu D, Pizzuti D, Moellering RC. In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. Antimicrob Agents Chemother. 1995 Apr; 39(4):850-3.
    View in: PubMed
  81. Eliopoulos GM. In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs. 1995; 49 Suppl 2:48-57.
    View in: PubMed
  82. Eliopoulos GM, Wennersten CB, Cole G, Moellering RC. In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother. 1994 Mar; 38(3):534-41.
    View in: PubMed
  83. Unal S, Werner K, DeGirolami P, Barsanti F, Eliopoulos G. Comparison of tests for detection of methicillin-resistant Staphylococcus aureus in a clinical microbiology laboratory. Antimicrob Agents Chemother. 1994 Feb; 38(2):345-7.
    View in: PubMed
  84. Pefanis A, Thauvin-Eliopoulos C, Holden J, Eliopoulos GM, Ferraro MJ, Moellering RC. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. Antimicrob Agents Chemother. 1994 Feb; 38(2):252-5.
    View in: PubMed
  85. Collins LA, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulos GM. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp. Antimicrob Agents Chemother. 1994 Jan; 38(1):144-6.
    View in: PubMed
  86. Malanoski GJ, Collins L, Wennersten C, Moellering RC, Eliopoulos GM. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1993 Sep; 37(9):2009-16.
    View in: PubMed
  87. Gold HS, Unal S, Cercenado E, Thauvin-Eliopoulos C, Eliopoulos GM, Wennersten CB, Moellering RC. A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother. 1993 Aug; 37(8):1604-9.
    View in: PubMed
  88. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC. Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis. J Antimicrob Chemother. 1993 Aug; 32(2):307-12.
    View in: PubMed
  89. Eliopoulos GM. Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1993 Jun; 12(6):409-12.
    View in: PubMed
  90. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Jun; 37(6):1364-6.
    View in: PubMed
  91. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother. 1993 Mar; 37(3):507-11.
    View in: PubMed
  92. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am. 1993 Mar; 7(1):117-33.
    View in: PubMed
  93. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar; 37(3):598-601.
    View in: PubMed
  94. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993 Feb; 16(2):111-8.
    View in: PubMed
  95. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis. 1993 Feb; 12(2):131-3.
    View in: PubMed
  96. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb; 37(2):366-70.
    View in: PubMed
  97. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol. 1992 Dec; 13(12):700-5.
    View in: PubMed
  98. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC. Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin. Antimicrob Agents Chemother. 1992 Nov; 36(11):2526-8.
    View in: PubMed
  99. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1992 Oct; 36(10):2201-3.
    View in: PubMed
  100. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother. 1992 Sep; 36(9):1864-9.
    View in: PubMed
  101. Eliopoulos GM, Thauvin-Eliopoulos C, Moellering RC. Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin. Clin Infect Dis. 1992 Jul; 15(1):58-62.
    View in: PubMed
  102. Malanoski GJ, Parker R, Eliopoulos GM. Antimicrobial susceptibilities of a Corynebacterium CDC group I1 strain isolated from a patient with endocarditis. Antimicrob Agents Chemother. 1992 Jun; 36(6):1329-31.
    View in: PubMed
  103. Rice LB, Eliopoulos CT, Yao JD, Eliopoulos GM, Moellering RC. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbiol Infect Dis. 1992 Feb; 15(2):173-6.
    View in: PubMed
  104. Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering RC. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother. 1992 Jan; 36(1):121-5.
    View in: PubMed
  105. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother. 1991 Nov; 35(11):2180-4.
    View in: PubMed
  106. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, Klimm K, Sapico FL, Bayer AS, Moellering RC. Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother. 1991 Jul; 35(7):1408-12.
    View in: PubMed
  107. Rice LB, Yao JD, Klimm K, Eliopoulos GM, Moellering RC. Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother. 1991 Jun; 35(6):1243-4.
    View in: PubMed
  108. Murray BE, Singh KV, Markowitz SM, Lopardo HA, Patterson JE, Zervos MJ, Rubeglio E, Eliopoulos GM, Rice LB, Goldstein FW, et al. Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis. 1991 Apr; 163(4):780-5.
    View in: PubMed
  109. Rice LB, Eliopoulos GM, Wennersten C, Goldmann D, Jacoby GA, Moellering RC. Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Feb; 35(2):272-6.
    View in: PubMed
  110. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis. 1991 Jan-Feb; 13(1):1-7.
    View in: PubMed
  111. Rhinehart E, Smith NE, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, Moellering RC, Goldmann DA. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990 Dec 27; 323(26):1814-8.
    View in: PubMed
  112. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jacoby GA. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990 Nov; 34(11):2193-9.
    View in: PubMed
  113. Hodges TL, Eliopoulos GM, Klimm K, Moellering RC. In vitro activity of BAY v 3522, a new cephalosporin for oral administration. Antimicrob Agents Chemother. 1990 Sep; 34(9):1849-54.
    View in: PubMed
  114. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, Yao JD, DeAngelis DV, Walton L, Woolley JL, Moellering RC. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1990 Sep; 34(9):1792-4.
    View in: PubMed
  115. Grayson ML, Eliopoulos GM. Antimicrobial resistance in the intensive care unit. Semin Respir Infect. 1990 Sep; 5(3):204-14.
    View in: PubMed
  116. Eliopoulos GM, Klimm K, Grayson ML. In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis. 1990 Jul-Aug; 13(4):345-8.
    View in: PubMed
  117. Eliopoulos GM, Klimm K, Rice LB, Ferraro MJ, Moellering RC. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother. 1990 Jun; 34(6):1154-9.
    View in: PubMed
  118. Thauvin-Eliopoulos C, Rice LB, Eliopoulos GM, Moellering RC. Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother. 1990 May; 34(5):728-32.
    View in: PubMed
  119. Yao JD, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1990 May; 34(5):827-30.
    View in: PubMed
  120. Kershaw P, Freeman R, Templeton D, DeGirolami PC, DeGirolami U, Tarsy D, Hoffmann S, Eliopoulos G, Karchmer AW. Pseudallescheria boydii infection of the central nervous system. Arch Neurol. 1990 Apr; 47(4):468-72.
    View in: PubMed
  121. Eliopoulos GM, Eliopoulos CT. Therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1990 Feb; 9(2):118-26.
    View in: PubMed
  122. Eliopoulos GM, Eliopoulos CT. Ciprofloxacin in combination with other antimicrobials. Am J Med. 1989 Nov 30; 87(5A):17S-22S.
    View in: PubMed
  123. Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis. 1989 Nov-Dec; 12(6):481-8.
    View in: PubMed
  124. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989 Oct; 8(10):888-9.
    View in: PubMed
  125. Eliopoulos GM. Synergism and antagonism. Infect Dis Clin North Am. 1989 Sep; 3(3):399-406.
    View in: PubMed
  126. Willey SH, Hindes RG, Eliopoulos GM, Moellering RC. Effects of clindamycin and gentamicin and other antimicrobial combinations against enterococci in an experimental model of intra-abdominal abscess. Surg Gynecol Obstet. 1989 Sep; 169(3):199-202.
    View in: PubMed
  127. Moellering RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989 Sep; 24 Suppl A:1-7.
    View in: PubMed
  128. Sentochnik DE, Eliopoulos GM, Ferraro MJ, Moellering RC. Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother. 1989 Aug; 33(8):1232-6.
    View in: PubMed
  129. Hindes RG, Willey SH, Eliopoulos GM, Rice LB, Eliopoulos CT, Murray BE, Moellering RC. Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989 Jul; 33(7):1019-22.
    View in: PubMed
  130. Eliopoulos GM, Klimm K, Ferraro MJ, Moellering RC. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates. Eur J Clin Microbiol Infect Dis. 1989 Jul; 8(7):624-6.
    View in: PubMed
  131. Yao JD, Eliopoulos GM, Moellering RC. In vitro activity of SK&F 104662, a new glycopeptide antibiotic. Antimicrob Agents Chemother. 1989 Jun; 33(6):965-7.
    View in: PubMed
  132. Rice LB, Eliopoulos GM, Moellering RC. In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother. 1989 Apr; 33(4):470-3.
    View in: PubMed
  133. Clyne CA, Eliopoulos GM. Fever and urticaria in acute giardiasis. Arch Intern Med. 1989 Apr; 149(4):939-40.
    View in: PubMed
  134. Eliopoulos GM, Reiszner E, Willey S, Novick WJ, Moellering RC. Effect of blood product medium supplements on the activity of cefotaxime and other cephalosporins against Enterococcus faecalis. Diagn Microbiol Infect Dis. 1989 Mar-Apr; 12(2):149-56.
    View in: PubMed
  135. Rice LB, Eliopoulos GM. Imipenem and aztreonam: current role in antimicrobial therapy. Curr Clin Top Infect Dis. 1989; 10:109-39.
    View in: PubMed
  136. Eliopoulos GM, Wennersten C, Zighelboim-Daum S, Reiszner E, Goldmann D, Moellering RC. High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother. 1988 Oct; 32(10):1528-32.
    View in: PubMed
  137. Daly JS, Eliopoulos GM, Willey S, Moellering RC. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988 Sep; 32(9):1341-6.
    View in: PubMed
  138. Eliopoulos GM. Induction of beta-lactamases. J Antimicrob Chemother. 1988 Jul; 22 Suppl A:37-44.
    View in: PubMed
  139. Daly JS, Eliopoulos GM, Reiszner E, Moellering RC. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988 Jun; 21(6):721-30.
    View in: PubMed
  140. Spitzer PG, Eliopoulos GM, Karchmer AW, Moellering RC. Synergistic activity between vancomycin or teicoplanin and gentamicin or tobramycin against pathogenic diphtheroids. Antimicrob Agents Chemother. 1988 Apr; 32(4):434-7.
    View in: PubMed
  141. Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev. 1988 Apr; 1(2):139-56.
    View in: PubMed
  142. Eliopoulos GM. New quinolones: pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency. Rev Infect Dis. 1988 Jan-Feb; 10 Suppl 1:S102-5.
    View in: PubMed
  143. Allan JD, Eliopoulos GM, Reiszner E, Moellering RC. In vitro activities of ICI 194008 and ICI 193428, two new cephem antimicrobial agents. Antimicrob Agents Chemother. 1987 Dec; 31(12):1997-2001.
    View in: PubMed
  144. Eliopoulos GM, Reiszner E, Ferraro MJ, Moellering RC. Comparative in-vitro activity of A-56268 (TE-031), a new macrolide antibiotic. J Antimicrob Chemother. 1987 Nov; 20(5):671-5.
    View in: PubMed
  145. Sherman ME, Albrecht M, DeGirolami PC, Kirkley SA, Wolf B, Eliopoulos GM, Rohrer RJ, Monaco AP. An unusual case of splenic abscess and sepsis in an immunocompromised host. Am J Clin Pathol. 1987 Nov; 88(5):659-62.
    View in: PubMed
  146. Hoffmann SA, Eliopoulos GM. Antibiotic resistance in the hospital setting: extent of the problem and possible solutions. Hosp Formul. 1987 Oct; 22(10):852-7, 860-3.
    View in: PubMed
  147. DeGirolami PC, Eliopoulos G. Antimicrobial susceptibility tests and their role in therapeutic drug monitoring. Clin Lab Med. 1987 Sep; 7(3):499-512.
    View in: PubMed
  148. Eliopoulos GM, Wennersten C, Reiszner E, Moellering RC. Comparative in vitro activity of CGP 31608, a new penem antibiotic. Antimicrob Agents Chemother. 1987 Aug; 31(8):1188-93.
    View in: PubMed
  149. Spitzer PG, Tarsy D, Eliopoulos GM. Acute transverse myelitis during disseminated cytomegalovirus infection in a renal transplant recipient. Transplantation. 1987 Jul; 44(1):151-3.
    View in: PubMed
  150. Eliopoulos G. Antibiotic synergism and antagonism: significance in clinical infections. Chemioterapia. 1987 Jun; 6(2 Suppl):188-90.
    View in: PubMed
  151. Eliopoulos GM, Reiszner E, Moellering RC. In vitro evaluation of the new paulomycin antibiotic paldimycin. Eur J Clin Microbiol. 1987 Jun; 6(3):306-8.
    View in: PubMed
  152. Spitzer PG, Eliopoulos GM, Karchmer AW, Moellering RC. Comparative in vitro activity of the new cyclic lipopeptide LY146032 against Corynebacterium species. Eur J Clin Microbiol. 1987 Apr; 6(2):183-5.
    View in: PubMed
  153. Eliopoulos GM, Reiszner E, Wennersten C, Moellering RC. In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Apr; 31(4):653-6.
    View in: PubMed
  154. Thauvin C, Eliopoulos GM, Willey S, Wennersten C, Moellering RC. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb; 31(2):139-43.
    View in: PubMed
  155. Eliopoulos GM, Reiszner E, Caputo GM, Moellering RC. In vitro activity of CI-934, a new quinolone antimicrobial, against gram-positive bacteria. Diagn Microbiol Infect Dis. 1986 Nov; 5(4):341-4.
    View in: PubMed
  156. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering RC. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct; 30(4):532-5.
    View in: PubMed
  157. Moellering RC, Eliopoulos GM, Allan JD. Beta-lactam/aminoglycoside combinations: interactions and their mechanisms. Am J Med. 1986 May 30; 80(5C):30-4.
    View in: PubMed
  158. Allan JD, Eliopoulos GM, Moellering RC. The expanding spectrum of beta-lactam antibiotics. Adv Intern Med. 1986; 31:119-46.
    View in: PubMed
  159. Eliopoulos GM, Moellering AE, Reiszner E, Moellering RC. In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother. 1985 Oct; 28(4):514-20.
    View in: PubMed
  160. Thauvin C, Eliopoulos GM, Wennersten C, Moellering RC. Antagonistic effect of penicillin-amikacin combinations against enterococci. Antimicrob Agents Chemother. 1985 Jul; 28(1):78-83.
    View in: PubMed
  161. Allan JD, Eliopoulos GM, Ferraro MJ, Moellering RC. Comparative in vitro activities of cefpiramide and apalcillin individually and in combination. Antimicrob Agents Chemother. 1985 May; 27(5):782-90.
    View in: PubMed
  162. Eliopoulos GM, Thauvin C, Gerson B, Moellering RC. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1985 Mar; 27(3):357-62.
    View in: PubMed
  163. Eliopoulos GM, Reiszner E, Moellering RC. In vitro activity of Sch 34343 against enterococci and other gram-positive bacteria. Antimicrob Agents Chemother. 1985 Jan; 27(1):28-32.
    View in: PubMed
  164. Moellering RC, Eliopoulos GM. Activity of cefotaxime against enterococci. Diagn Microbiol Infect Dis. 1984 Jun; 2(3 Suppl):85S-90S.
    View in: PubMed
  165. Eliopoulos GM, Gardella A, DeGirolami P, Moellering RC. In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates. Antimicrob Agents Chemother. 1984 Apr; 25(4):401-4.
    View in: PubMed
  166. Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med. 1984 Apr; 100(4):533-4.
    View in: PubMed
  167. Eliopoulos GM, Farber BF, Murray BE, Wennersten C, Moellering RC. Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother. 1984 Mar; 25(3):398-9.
    View in: PubMed
  168. Eliopoulos GM, Gardella A, Moellering RC. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar; 25(3):331-5.
    View in: PubMed
  169. Farber BF, Eliopoulos GM, Ward JI, Ruoff K, Moellering RC. Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother. 1983 Dec; 24(6):871-5.
    View in: PubMed
  170. Knapp AB, Horst DA, Eliopoulos G, Gramm HF, Gaber LW, Falchuk KR, Falchuk ZM, Trey C. Widespread cytomegalovirus gastroenterocolitis in a patient with acquired immunodeficiency syndrome. Gastroenterology. 1983 Dec; 85(6):1399-402.
    View in: PubMed
  171. Farber BF, Eliopoulos GM, Ward JI, Ruoff KL, Syriopoulou V, Moellering RC. Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother. 1983 Nov; 24(5):702-5.
    View in: PubMed
  172. Moellering RC, Willey S, Eliopoulos GM. Synergism and antagonism of ceftizoxime and other new cephalosporins. J Antimicrob Chemother. 1982 Nov; 10 Suppl C:69-79.
    View in: PubMed
  173. Eliopoulos GM, Moellering RC. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982 Nov; 97(5):755-60.
    View in: PubMed
  174. Eliopoulos GM, Wennersten C, Moellering RC. Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother. 1982 Aug; 22(2):295-301.
    View in: PubMed
  175. Eliopoulos GM, Moellering RC. Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis. 1982 Mar-Apr; 4(2):282-93.
    View in: PubMed
  176. Eliopoulos GM, Gardella A, Moellering RC. In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother. 1982 Feb; 9 Suppl C:143-52.
    View in: PubMed
  177. Eliopoulos GM, Moellering RC. Principles of antibiotic therapy. Med Clin North Am. 1982 Jan; 66(1):3-15.
    View in: PubMed
  178. Eliopoulos GM, Moellering RC. Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1981 May; 19(5):789-93.
    View in: PubMed
  179. Eliopoulos G, Daniels GH, Maloof F. Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease. Arch Intern Med. 1975 Sep; 135(9):1242-4.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Eliopoulos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (459) concept(s)
_
Co-Authors
See all (22) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_